Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | PRKCB | P05771 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | RB1 | P06400 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087781 | 0.98 | LMNA (0.55) | LMNAKMT2AHTTPRKCBRAB9A | |
| SCHEMBL21047740 | 0.84 | PRKCB (0.46) | LMNAKMT2AHTTPRKCBRAB9A | |
| SCHEMBL28615180 | 0.78 | HTT (0.40) | LMNAKMT2AHTTPRKCBRAB9A | |
| SCHEMBL27553065 | 0.74 | MTNR1A (0.57) | RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4495740 | 0.73 | KDM4E (0.73) | LMNAKMT2AHTTRAB9ANPC1 | |
| SCHEMBL11523761 | 0.73 | KDM4E (0.73) | LMNAKMT2AHTTRAB9ANPC1 | |
| SCHEMBL20336230 | 0.73 | KDM4E (0.73) | LMNAKMT2AHTTRAB9ANPC1 | |
| SCHEMBL29449726 | 0.73 | KDM4E (0.73) | LMNAKMT2AHTTRAB9ANPC1 | |
| SCHEMBL6654114 | 0.72 | ATM (0.52) | KMT2AHTTKDM4EMAPTMEN1 | |
| SCHEMBL7840105 | 0.71 | PRKCB (1.00) | PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | claimed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-2536717-B1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-04 | — | — | EP | disclosed |
| EP-2536716-B1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-8580832-B2 | Substituted phenoxy aminothiazolones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-12 | — | — | US | disclosed |
| US-8445690-B2 | Aminothiazolones as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-21 | — | — | US | disclosed |
| US-8426604-B2 | Aminothiazolones as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-23 | — | — | US | disclosed |
| US-8399681-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8344009-B2 | Substituted phenoxy thiazolidinediones as estrogen related receptor-á modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | disclosed |
| CN-1304409-A | Indol-3-Yl-cyclohexyl amide derivatives for treatment of depression (5-HT1 receptor antagonists) | AMERICAN HOME PROD (US) | 2001-07-18 | — | — | CN | disclosed |
| EP-1070063-A1 | INDOL-3-YL-CYCLOHEXYL AMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION (5-HT1 RECEPTOR ANTAGONISTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-1070712-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING ANTIPLATELET AGGREGATION EFFECT AND MEDICINAL USE THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6162803-A | Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression | AMERICAN HOME PRODUCTS CORP. (US) | 2000-12-19 | — | — | US | disclosed |
| US-6162803-A | Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression | AMERICAN HOME PRODUCTS CORP. (US) | 2000-12-19 | — | — | US | disclosed |
| WO-1999051592-A1 | INDOL-3-YL-CYCLOHEXYL AMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION (5-HT1 RECEPTOR ANTAGONISTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | HTR5A, HTR1A, HTR3A | LMNA 2791/4885KMT2A 3907/4885HTT 2642/4885 |
| US-20080221179-A1 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators | ESR2, ESRRA, ESRRG | LMNA 3434/4885KMT2A 970/4885HTT 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.